echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Regorafenib combined with orvizumab in the treatment of microsatellite stable advanced colorectal cancer

    Clin Cancer Res: Regorafenib combined with orvizumab in the treatment of microsatellite stable advanced colorectal cancer

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide.


    Colorectal cancer blood vessels

    Regorafenib is a small molecule tyrosine kinase inhibitor.


    Regorafenib is a small molecule tyrosine kinase inhibitor.


    immunity

    This study is a single-arm, multi-center phase II trial.


    PFS and OS in microsatellite-stabilized patients treated with regorafenib + orvizumab

    PFS and OS in microsatellite-stabilized patients treated with regorafenib + orvizumab

    A total of 48 patients were recruited from 4 centers, and 43 of them could be evaluated for efficacy.


    The best response is to maintain a stable condition, seen in 23 (53.


    The prediction of tumor infiltration of CD163+ macrophages on the prognosis of patients

    The prediction of tumor infiltration of CD163+ macrophages on the prognosis of patients

    High baseline infiltration of tumor-associated macrophages was significantly associated with poor PFS (1.


    High baseline infiltration of tumor-associated macrophages was significantly associated with poor PFS (1.


    In short, mAb Orville Ruige Fini joint portion can be mobilized anti microsatellite stable patients with colorectal cancer tumor immunity force.


    Original source:

    Sophie Cousin, et al.


    aacrjournals.
    org/content/27/8/2139" target="_blank" rel="noopener">Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.